Stanniocalcin stimulates phosphate reabsorption by flounder renal proximal tubule in primary culture.
The effects of several hormones on transepithelial Pi transport were determined in primary monolayer cultures of winter flounder proximal tubule epithelium in Ussing chambers. Salmon stanniocalcin (STC) had a dose-dependent stimulatory effect on net Pi reabsorption within the normal plasma hormone concentration range, 12.5-50 ng/ml (0.25-1.0 nM). Net Pi transport was significantly altered by STC (200 ng/ml) within 30 min and progressively increased from slight net secretion (0.26 +/- 0.744 nmol.cm-2.h-1) in untreated controls to net reabsorption (1.96 +/- 0.729 nmol.cm-2.h-1) after 3 h. The STC effect was mimicked by 10 microM forskolin, whereas 10 microM H-89, a highly specific protein kinase A inhibitor, significantly decreased both STC- and forskolin-induced Pi reabsorption. The release of adenosine 3',5'-cyclic monophosphate (cAMP) was increased more than twofold after a 1-h exposure to STC. This hormone had no effect on transepithelial Ca2+ transport. The results indicate that STC directly stimulates net renal Pi reabsorption by a cAMP-dependent pathway. In addition to STC, bovine parathyroid hormone (100 nM) and ovine prolactin (100 nM) significantly increased net Pi reabsorptive flux.
Lu
M
M
Department of Physiology and Neurobiology, University of Connecticut, Storrs 06269-3042.
Wagner
G F
GF
Renfro
J L
JL
D000042:Absorption; D000818:Animals; D009320:Atrial Natriuretic Factor / Q000494:pharmacology; D002116:Calcitonin / Q000031:analogs & derivatives / Q000494:pharmacology; D002117:Calcitriol / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism; D002417:Cattle; D002478:Cells, Cultured; D005576:Colforsin / Q000494:pharmacology; D003470:Culture Media; D000242:Cyclic AMP / Q000378:metabolism; D004298:Dopamine / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004837:Epinephrine / Q000494:pharmacology; D004848:Epithelium / Q000187:drug effects / Q000502:physiology; D005432:Flounder; D006023:Glycoproteins / Q000494:pharmacology*; D013006:Growth Hormone / Q000494:pharmacology; D006728:Hormones / Q000494:pharmacology*; D007546:Isoquinolines / Q000494:pharmacology; D007687:Kidney Tubules, Proximal / Q000187:drug effects / Q000502:physiology*; D007700:Kinetics; D008564:Membrane Potentials / Q000187:drug effects; D010281:Parathyroid Hormone / Q000494:pharmacology; D010710:Phosphates / Q000493:pharmacokinetics*; D011388:Prolactin / Q000494:pharmacology; D047428:Protein Kinase Inhibitors; D013449:Sulfonamides; D013997:Time Factors; D014284:Triiodothyronine / Q000494:pharmacology
D003470:Culture Media; D006023:Glycoproteins; D006728:Hormones; D007546:Isoquinolines; D010281:Parathyroid Hormone; D010710:Phosphates; D047428:Protein Kinase Inhibitors; D013449:Sulfonamides; D014284:Triiodothyronine; D005576:Colforsin; C051795:teleocalcin; D009320:Atrial Natriuretic Factor; D011388:Prolactin; D013006:Growth Hormone; D002116:Calcitonin; D000242:Cyclic AMP; D002117:Calcitriol; C063509:N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide; D002118:Calcium; D004298:Dopamine; D004837:Epinephrine